Tolerability and Safety of Biological Therapies for Psoriasis in Daily Clinical Practice: A Study of 103 Italian Patients
Tolerability and Safety of Biological Therapies for Psoriasis in Daily Clinical Practice: A Study of 103 Italian Patients
复制标题
DOI：
10.2340/00015555-0959
复制
发表时间：
2011-01-01
影响因子：
3.6
通讯作者：
Massone, Cesare
中科院分区：
文献类型：
--
作者：
Brunasso, Alexandra Maria Giovanna;Puntoni, Matteo;Massone, Cesare
缺乏长期和日常临床实践中比较牛皮癣生物疗法的安全性和耐受性的研究。大多数已发表的研究都是对选定的患者进行短期(3-6个月)的随访。我们对103名患者进行了一项回顾性队列研究，以描述不良事件的频率和临床特征，并评估和比较依那西普、英夫利昔单抗和阿达利单抗在临床应用中的耐受性和安全性。总共进行了136个疗程的生物治疗，平均疗程为16个月/患者；55名患者接受了efalizumab，45名患者接受了etanercept，33名患者接受了英夫利昔单抗，3名患者接受了adalimumab。英夫利昔单抗因严重不良事件而停用的发生率比为5.9倍(95%可信区间(95%CI)1.9-18，p
Studies comparing the safety and tolerability of biological therapies for psoriasis in the long-term and in daily clinical practice are lacking. Most published studies are of selected patients with short-term (3-6 months) follow-up. We performed a retrospective cohort study of 103 patients in order to describe the frequency and the clinical features of adverse events, and to evaluate and compare the tolerability and safety of efalizumab, etanercept, infliximab, and adalimumab in clinical practice. A total of 136 courses of biological therapies were administered, with a mean duration of 16 months/patient; 55 patients received efalizumab, 45 etanercept, 33 infliximab, and 3 adalimumab. Infliximab had an incidence rate ratio of suspension due to severe adverse events 5.9 times (95% confidence interval (95% Cl) 1.9-18, p